Author | S. K. Klein

Articles

Phase II Study of Rituximab in Combination With Fludarabine in Patients With Chronic Lymphocytic Leukemia

March 01, 2002

ByH. Schulz|S. K. Klein|U. Rehwald|Maximilian F. Reiser, MD|S. Ibach|W. E. Aulitzky|M. Hensel|M. Herold|D. Huhn|U. Knauf|Michael Hallek, MDDirector|Volker Diehl, MD, PhD|Andreas Engert, MD, PhD

This phase II trial investigated the safety and efficacy of a combined-modality treatment with rituximab (Rituxan) and fludarabine (Fludara) in patients with fludarabine- and anthracycline-naive chronic lymphocytic lymphoma (CLL).